[go: up one dir, main page]

MA31385B1 - Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse - Google Patents

Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse

Info

Publication number
MA31385B1
MA31385B1 MA32356A MA32356A MA31385B1 MA 31385 B1 MA31385 B1 MA 31385B1 MA 32356 A MA32356 A MA 32356A MA 32356 A MA32356 A MA 32356A MA 31385 B1 MA31385 B1 MA 31385B1
Authority
MA
Morocco
Prior art keywords
treatment
hdac inhibitors
bone destruction
bone
destruction
Prior art date
Application number
MA32356A
Other languages
Arabic (ar)
English (en)
Inventor
Peter Wisdom Atadja
Joseph Daniel Growney
Wenlin Shao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39643800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31385(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31385B1 publication Critical patent/MA31385B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention concerne une utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse causée par le cancer, des maladies inflammatoires et l'ostéoporose.
MA32356A 2007-05-30 2009-11-20 Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse MA31385B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94073507P 2007-05-30 2007-05-30
PCT/US2008/064944 WO2008150782A1 (fr) 2007-05-30 2008-05-28 Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse

Publications (1)

Publication Number Publication Date
MA31385B1 true MA31385B1 (fr) 2010-05-03

Family

ID=39643800

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32356A MA31385B1 (fr) 2007-05-30 2009-11-20 Utilisation d'inhibiteurs de hdac pour le traitement de la destruction osseuse

Country Status (20)

Country Link
US (2) US20100179208A1 (fr)
EP (1) EP2162129B1 (fr)
JP (1) JP2010529028A (fr)
KR (1) KR101516446B1 (fr)
CN (1) CN101715344A (fr)
AU (1) AU2008260236A1 (fr)
BR (1) BRPI0812788A2 (fr)
CA (1) CA2687274A1 (fr)
CL (1) CL2008001553A1 (fr)
DK (1) DK2162129T3 (fr)
ES (1) ES2726401T3 (fr)
IL (1) IL201466A0 (fr)
LT (1) LT2162129T (fr)
MA (1) MA31385B1 (fr)
MX (1) MX2009012624A (fr)
RU (1) RU2009148601A (fr)
SI (1) SI2162129T1 (fr)
TN (1) TN2009000448A1 (fr)
TW (1) TW200904412A (fr)
WO (1) WO2008150782A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0909159A2 (pt) 2008-03-26 2015-11-24 Novartis Ag inibidores baseados em hidroxamato de desacetilases b
US20110053925A1 (en) * 2009-08-28 2011-03-03 Novartis Ag Hydroxamate-Based Inhibitors of Deacetylases
CN115778950B (zh) * 2022-11-23 2024-01-26 山西医科大学第二医院 组蛋白去乙酰化酶抑制剂tmp195在制备促进成骨形成药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2006278718B2 (en) * 2005-08-03 2010-10-07 Secura Bio Inc. Use of HDAC inhibitors for the treatment of myeloma

Also Published As

Publication number Publication date
IL201466A0 (en) 2010-05-31
CA2687274A1 (fr) 2008-12-11
EP2162129A1 (fr) 2010-03-17
TN2009000448A1 (en) 2011-03-31
CN101715344A (zh) 2010-05-26
US20120029047A1 (en) 2012-02-02
US20100179208A1 (en) 2010-07-15
EP2162129B1 (fr) 2019-03-06
JP2010529028A (ja) 2010-08-26
DK2162129T3 (da) 2019-06-11
MX2009012624A (es) 2009-12-07
RU2009148601A (ru) 2011-07-10
BRPI0812788A2 (pt) 2014-12-02
CL2008001553A1 (es) 2009-06-05
AU2008260236A1 (en) 2008-12-11
TW200904412A (en) 2009-02-01
KR101516446B1 (ko) 2015-04-30
LT2162129T (lt) 2019-06-25
KR20100017434A (ko) 2010-02-16
ES2726401T3 (es) 2019-10-04
WO2008150782A1 (fr) 2008-12-11
SI2162129T1 (sl) 2019-08-30

Similar Documents

Publication Publication Date Title
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
MA31918B1 (fr) Agents et épitopes de liaison à wise
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
NO20081636L (no) FAP - inhibitorer
MA35638B1 (fr) 2-thiopyrimidinones
TW200626068A (en) Active compounds for seed treatment
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MX373783B (es) Composiciones farmacéuticas que comprenden epa y un agente cardiovascular y métodos para utilizar el mismo.
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
MX2009003981A (es) Agentes moduladores del receptor de calcio.
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
EA200602129A1 (ru) Новое применение пептидных соединений для лечения дискинезии
CY1114023T1 (el) Διυποκατεστημενης φθαλαζινης ανταγωνιστες σηματοδοτικης οδου hedgehog
EA201170344A1 (ru) Азаиндольные ингибиторы iap
EP2225196A4 (fr) Inhibiteurs de cystéine-protéases pour le traitement de maladies parasitaires
TN2012000301A1 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
NZ593019A (en) Il-3 inhibitors in use for treatment of rheumatoid arthritis in an early stage
FR2879598B1 (fr) Inhibiteurs de phosphatases cdc25